When something like three in four venture-backed startups fail, picking the ones that won’t is definitely not an easy feat.
In search of what they call the “unicorn VCs” of healthcare – investors who have consistently invested in companies with the biggest of the big exits – analysts at research firm CB Insights combed through a decade of healthcare M&A data. They found 50 medical device and biotech companies that exited, through IPO or acquisition, with valuations of at least $500 million between 2004 and 2013.